Selecting the best tyrosine kinase inhibitors for chronic phase CML patients involves understanding various options, including first and second-generation TKIs. Factors like cost, accessibility, and patient preferences are crucial. Dosing strategies, especially for dasatinib, show that lower doses can improve outcomes. The concept of drug-free remission is significant, and quality of life remains a priority. Tailoring treatment to individual circumstances, including pregnancy, is essential for effective care.